Aspen eyes more overseas buys after recent deals pay off

South Africa-based Aspen Pharmacare, encouraged by the payoff from $2 billion worth of recent international buys, is looking for more overseas products and companies to snap up. CEO Stephen Saad tells Reuters that he's "looking the hardest" in Asia. Report

Suggested Articles

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.